Black Rock Inc. Coherus Bio Sciences, Inc. Call Options Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CHRS
# of Institutions
140Shares Held
75.9MCall Options Held
79.1KPut Options Held
100K-
Vanguard Group Inc Valley Forge, PA10.6MShares$7.85 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$7.7 Million0.53% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$2.25 Million0.3% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.84MShares$2.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.38MShares$1.76 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $57.5M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...